BTIG raised the firm’s price target on Avalo Therapeutics (AVTX) to $58 from $40 and keeps a Buy rating on the shares. The firm is citing the company’s announcement of positive topline results in the Phase 2 LOTUS trial of Abdakibart, increasing the probability of success in hidradenitis suppurativa to 85%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Morning News Wrap-Up, 5/6/26: Today’s Biggest Stock Market Stories!
- Why Is Avalo Therapeutics Stock (AVTX) Up Today?
- Julian Harrison Raises AVTX Price Target to $58 on Strong Phase 2 LOTUS Data and Differentiated Safety Profile for Abdakibart
- Avalo Therapeutics Reports Strong Phase 2 Hidradenitis Data
- Avalo Therapeutics announces common stock and warrants offering, no amount given